JAZZ Form 4: Director Bruce Cozadd Withholds 15,647 Shares to Cover Taxes
Rhea-AI Filing Summary
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported a transaction on 09/14/2025. The Form 4 shows 15,647 ordinary shares were disposed under code F(1) at a price of $126.16 per share. The filing explains the shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
After the withholding, Mr. Cozadd beneficially owns 414,326 ordinary shares (reported as direct ownership). The Form 4 was signed on 09/17/2025 by an attorney-in-fact, and the reporting person is identified with an address in Dublin and relationship as Director.
Positive
- Transparent disclosure of insider share change via Form 4, including explanation for withholding
- Continued significant ownership with 414,326 ordinary shares reported after the transaction
Negative
- Reduction in direct holdings of 15,647 shares due to tax-withholding on vested RSUs
Insights
TL;DR: Routine tax withholding from RSU vesting resulted in a partial disposition of 15,647 shares; no unusual insider selling.
The reported transaction is coded F(1), which the filer explains as shares withheld to satisfy tax obligations related to RSU vesting. This is a common administrative disposition that reduces the insider's share count by the withheld amount rather than representing an open-market sale. The price per share reported ($126.16) reflects the value used for the withholding calculation on 09/14/2025. Because the report shows continued direct beneficial ownership of 414,326 shares, the filing indicates ongoing insider alignment with shareholder interests rather than a deliberate liquidity event.
TL;DR: Filing documents compliant insider reporting and routine tax-related share withholding following RSU vesting.
The Form 4 identifies the reporting person as a director and documents the administrative withholding of 15,647 ordinary shares to satisfy tax obligations from vested RSUs. The form is signed by an attorney-in-fact and provides clear explanation of the transaction code. From a governance standpoint, this disclosure meets Section 16 reporting requirements and preserves transparency about changes in insider ownership levels.